Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 2/20 | 0.31 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20429044 | 0.96 | GAA (0.37) | GAA | |
| SCHEMBL20445646 | 0.95 | GAA (0.36) | GAA | |
| SCHEMBL11500771 | 0.90 | GAA (0.41) | GAANAAA | |
| SCHEMBL20438824 | 0.89 | GAA (0.33) | GAA | |
| SCHEMBL11170098 | 0.88 | GAA (0.42) | GAANAAA | |
| SCHEMBL20429046 | 0.87 | GAA (0.34) | GAA | |
| SCHEMBL20439109 | 0.85 | GAA (0.34) | GAANAAA | |
| SCHEMBL20429074 | 0.84 | FDPS (0.30) | — | |
| SCHEMBL20428971 | 0.83 | EPHX2 (0.36) | GAANAAA | |
| SCHEMBL26482189 | 0.83 | NAAA (0.40) | GAANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024126567-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2024-06-20 | — | — | WO | disclosed |
| EP-4306614-A1 | LIQUID-CRYSTALLINE MEDIUM | Merck Patent GmbH (DE) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023198671-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023198673-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023198669-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2023-10-19 | — | — | WO | disclosed |
| EP-4261269-A1 | LIQUID-CRYSTALLINE MEDIUM | Merck Patent GmbH (DE) | 2023-10-18 | — | — | EP | disclosed |
| US-20230323207-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2023-10-12 | — | — | US | disclosed |
| US-20230323207-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2023-10-12 | — | — | US | disclosed |
| EP-4008759-A1 | POLYMERISABLE LIQUID CRYSTAL MATERIAL AND POLYMERISED LIQUID CRYSTAL FILM | Merck Patent GmbH (DE) | 2022-06-08 | — | — | EP | disclosed |
| US-20220162504-A1 | Polymerisable Liquid Crystal Material and Polymerised Liquid Crystal Film | MERCK PATENT GMBH (DE) | 2022-05-26 | — | — | US | disclosed |
| WO-2021219765-A1 | POLYMERIZABLE LIQUID CRYSTAL MATERIAL AND POLYMERIZED LIQUID CRYSTAL FILM | MERCK PATENT GMBH (DE) | 2021-11-04 | — | — | WO | disclosed |
| US-10913897-B2 | Compounds and liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2021-02-09 | — | — | US | disclosed |
| EP-3354710-B1 | COMPOUNDS AND LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2020-12-23 | — | — | EP | disclosed |
| WO-2019228939-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-12-05 | — | — | WO | disclosed |
| WO-2019228938-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-12-05 | — | — | WO | disclosed |
| US-20180216005-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-08-02 | — | — | US | disclosed |
| US-20180216005-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-08-02 | — | — | US | disclosed |
| EP-3354710-A1 | COMPOUNDS AND LIQUID CRYSTALLINE MEDIUM | Merck Patent GmbH (DE) | 2018-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913897-B2 | Compounds and liquid-crystalline medium | VIM, NEFM, AQP1 | GAA 4024/4885NAAA 4015/4885SMPD1 2783/4885 |
| US-20180216005-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | VIM, NEFM, AQP1 | GAA 4024/4885NAAA 4015/4885SMPD1 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.